We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
At $1.8 billion and growing 10 percent annually, the Russian market for medical equipment is lucrative for devicemakers who know how to navigate the country’s dual regulatory system.
One in three doctors believe that their decisions on which drugs to prescribe have been affected by receiving drug samples from pharmaceutical sales representatives, indicating that the practice needs to be examined more carefully, according to a study of doctors published in the Journal of Medical Ethics.
Close to half of the U.S. population does not fully understand the information on drug websites that target consumers, according to an analysis — further evidence of “a serious, serious problem” in consumers’ understanding of medicines and how to take them, according to one consumer advocate.
Delayed drug approvals have caused Altana Pharma to dismantle its marketing and sales organization in Florham Park, N.J. by the end of the year, the company announced Oct. 3.
The Association of the British Pharmaceutical Industry (ABPI) has suspended Merck Sharp & Dohme (MSD) for at least three months for violations of the industry group’s code of ethics.
The fact that the newest generation of antipsychotic drugs used to treat schizophrenia is no more effective than earlier, less expensive treatments illustrates the need for a national dialogue about comparative effectiveness between drug classes, an academic says.
Barr Pharmaceutical announced Sept. 28 that it is now free to close a deal with Shire, acquiring the rights to Shire’s attention-deficit/
hyperactivity disorder drug Adderall immediate-release (IR) tablets.
Pharmaceutical industry growth has made a geographic shift in the last few years from the U.S. to other countries and will continue to materialize abroad, one analyst said at a recent industry conference.
The overall cholesterol drug market is growing faster than anticipated, with the introduction of generic Zocor not hurting the competition, according to one analyst.
Versions of biologic products should not be lumped together
as a homogenous group, but rather placed into separate categories
depending on qualities such as structure and efficacy, one drugmaker said at a recent industry conference.